Biomarkers

Why does tau-PET not detect the earliest stages of Alzheimer’s disease?

Latest knowledge on plasma p-tau in Alzheimer’s disease

Alzheimer’s disease subtypes identified based on blood proteomics

Correlation between synaptic biomarkers and known CSF biomarkers in Alzheimer’s disease

CSF synaptic markers in Alzheimer’s disease

Establishing the UK DRI Biomarker Factory

Access to Alzheimer’s disease diagnostic biomarkers in clinical routine

A future scenario: digital and blood biomarkers for Alzheimer’s disease diagnosis in primary care

How can researchers use the UK DRI Biomarker Factory?

Current and future role of tau-PET in dementia daily practice

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Remaining challenges in bringing fluid biomarkers into clinical practice

Bringing the pTau/Aβ42 biomarker into the clinic

Promise of microRNAs as Alzheimer’s disease markers

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

The importance of using systems biology based approaches in AD research